1-3 of 3
Katherine Ryland
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update

Andrew Bruce McDonald, Estelle Verburgh, Manuel Gotti, Antonio Pinto, Jan M. Zaucha, Vladimir Ivanov, Vladimir Melnichenko, Heidi Mocikova, Muhit Ozcan, Caterina Patti, João Farias, Iara Zapparoli Goncalves, Olha Kuchkova, Jiri Mayer, Güray Saydam, Sarah Tomassetti, Kumudu Pathiraja, Katherine Ryland, Rushdia Yusuf, Wojciech Jurczak
Journal: Blood
Blood (2024) 144 (Supplement 1): 3046.
https://doi.org/10.1182/blood-2024-200323
Published: 2024
Journal Articles

Zilovertamab Vedotin in Combination with Nemtabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort C of the Open-Label, Phase 2 Waveline-006 Study

Ewa Paszkiewicz-Kozik, Claudia Moreira, Mehmet Turgut, Marcelo Garrido, Ingrid Glimelius, Seung Tae Lee, Yazeed Sawalha, Yixin Ren, Katherine Ryland, Uzor C. Ogbu, Diego Villa
Journal: Blood
Blood (2024) 144 (Supplement 1): 3025.
https://doi.org/10.1182/blood-2024-205985
Published: 2024
Journal Articles

Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study

Ingrid Glimelius, Won Seog Kim, Ewa Paszkiewicz-Kozik, Daniel Ernst, Reid W. Merryman, Claudia Moreira, Sanfang Tu, Yixin Ren, Katherine Ryland, Uzor C. Ogbu, Pier Luigi Zinzani
Journal: Blood
Blood (2024) 144 (Supplement 1): 4405.
https://doi.org/10.1182/blood-2024-205897
Published: 2024